These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34696438)

  • 21. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA.
    Hosui A; Tanimoto T; Okahara T; Ashida M; Ohnishi K; Wakahara Y; Kusumoto Y; Yamaguchi T; Sueyoshi Y; Hirao M; Yamada T; Hiramatsu N
    Hepatol Commun; 2021 Dec; 5(12):2001-2008. PubMed ID: 34752016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
    Sugiura A; Joshita S; Umemura T; Yamazaki T; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Usami Y; Wada S; Mori H; Shibata S; Yoshizawa K; Morita S; Furuta K; Kamijo A; Iijima A; Kako S; Maruyama A; Kobayashi M; Komatsu M; Matsumura M; Miyabayashi C; Ichijo T; Takeuchi A; Koike Y; Gibo Y; Tsukadaira T; Inada H; Kiyosawa K; Tanaka E
    J Viral Hepat; 2018 Dec; 25(12):1462-1471. PubMed ID: 30044517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
    Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
    PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma.
    Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS
    J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
    El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
    Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
    Bitetto D; Fattovich G; Fabris C; Ceriani E; Falleti E; Fornasiere E; Pasino M; Ieluzzi D; Cussigh A; Cmet S; Pirisi M; Toniutto P
    Hepatology; 2011 Apr; 53(4):1118-26. PubMed ID: 21480318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Van Renne N; Roca Suarez AA; Duong FHT; Gondeau C; Calabrese D; Fontaine N; Ababsa A; Bandiera S; Croonenborghs T; Pochet N; De Blasi V; Pessaux P; Piardi T; Sommacale D; Ono A; Chayama K; Fujita M; Nakagawa H; Hoshida Y; Zeisel MB; Heim MH; Baumert TF; Lupberger J
    Gut; 2018 May; 67(5):953-962. PubMed ID: 28159835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Ghanm SE; Shebl NA; El Sayed IET; Abdel-Bary HM; Saad BF; Othman Saad W
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3203-3210. PubMed ID: 34710996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
    Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M;
    Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    Beste LA; Green PK; Berry K; Kogut MJ; Allison SK; Ioannou GN
    J Hepatol; 2017 Jul; 67(1):32-39. PubMed ID: 28267622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HMGB1 and SEPP1 as predictors of hepatocellular carcinoma in patients with viral C hepatitis: Effect of DAAs.
    Rizk NI; Sallam AM; El-Ansary AR; El-Mesallamy HO
    Clin Biochem; 2019 Aug; 70():8-13. PubMed ID: 31158358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
    Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
    Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma.
    Elbaz T; Waked I; El-Akel W; Shaker MK; Abdelaziz AO; Yousif M; El-Bendary M; Zaky S; AbdAllah M; Hassany M; Esmat G; Doss W
    Expert Rev Anti Infect Ther; 2022 Feb; 20(2):307-314. PubMed ID: 34253123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents.
    Suzuki T; Matsuura K; Nagura Y; Kawamura H; Fujiwara K; Ogawa S; Nagaoka K; Iio E; Watanabe T; Kataoka H; Tanaka Y
    Oncology; 2024; 102(7):611-620. PubMed ID: 38211572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D deficiency: correlation to interleukin-17, interleukin-23 and PIIINP in hepatitis C virus genotype 4.
    Schaalan MF; Mohamed WA; Amin HH
    World J Gastroenterol; 2012 Jul; 18(28):3738-44. PubMed ID: 22851868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.